Assignee
RNA THERAPEUTICS INC
US·0 granted patents·42 pending applications·0 citations·filing 2024–2024
Top patents by PatentIndex Score
42 records- 0170US2026035442A1Single-chain crenezumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0270US2026062489A1Single-chain teprotumumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0370US2026042830A1Single-chain infliximab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0470US2026049153A1Single-chain ofatumumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0570US2026028413A1Single-chain alemtuzumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0670US2026049147A1Single-chain natalizumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0770US2026042832A1Single-chain guselkumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0870US2026055170A1Single-chain romosozumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0970US2026035443A1Single-chain donanemab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1070US2026055174A1Single-chain risankizumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1170US2026022163A1Single-chain aducanumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1270US2026049125A1Single-chain prasinezumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1370US2026042824A1Single-chain exidavnemab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1470US2026042823A1Single-chain eculizumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1570US2026062468A1Single-chain tilavonemab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1670US2026022167A1Single chain adalimumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1770US2026062473A1Single-chain tildrakizumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1870US2026049152A1Single-chain ocrelizumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1970US2026055166A1Single-chain ravulizumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2070US2026042825A1Single-chain gantenerumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2170US2026071004A1Single-chain trastuzumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2270US2026070968A1Single-chain ustekinumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2370US2026042852A1Single-chain dupilumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2470US2026062467A1Single-chain solanezumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2570US2026055175A1Single-chain secukinumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2670US2026042826A1Single-chain gosuranemab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2770US2026049124A1Single-chain lecanemab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2870US2026035441A1Single-chain cinpanemab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2970US2026049129A1Single-chain ranibizumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3070US2026028394A1Single-chain aflibercept antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3170US2026028411A1Single-chain belimumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3270US2026078174A1Single-chain medi1341 antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3370US2026055196A1Single-chain romiplostim antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3470US2026035454A1Single-chain canakinumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3570US2026055167A1Single-chain semorinemab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3670US2026028408A1Single-chain basiliximab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3770US2026042833A1Single-chain ixekizumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3870US2026035470A1Single-chain cetuximab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3970US2026078173A1Single-chain zagotenemab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4070US2026035446A1Single-chain brolucizumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4170US2026035445A1Single-chain bevacizumab antibody-transferrin fusion protein for enhanced efficacy and indicationsRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4270US2026008838A1Multi-target alzheimer's treatmentRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when RNA THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →